[{"orgOrder":0,"company":"Porton Biopharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Asparaginase","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Porton Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Lyophilized Powder for Solution","sponsorNew":"Porton Biopharma \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Porton Biopharma \/ Clinigen Group"}]

Find Clinical Drug Pipeline Developments & Deals by Porton Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CRS
                          Not Confirmed
                          CRS
                          Not Confirmed

                          Details : Under the terms of the agreement, Clinigen will distribute Erwinase®/ Erwinaze®, the Porton's life-saving treatment for acute lymphoblastic leukaemia.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          April 16, 2020

                          Lead Product(s) : Asparaginase

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Clinigen Group

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank